The Effect of Flunarizine Treatment on Human Red Blood Cells

Abstract

In a first group of experiments, control and ischemic blood was sampled from healthy male volunteers before and 3 hours after the administration of a single 40-mg oral dose of flunarizine or placebo. The blood samples were stored for 24 hours at 0°C to induce partial transformation of discocytes into echi nocytes (crenation). The effect of the drug on the degree of crenation was evaluated by scanning electron microscopy. In control blood, flunarizine treat ment significantly suppressed the discocyte-echinocyte transformation. Similar results were obtained with ischemic blood, although individual variability was greater.

In a second group of experiments still in progress, control blood was taken from patients with intermittent claudication before and 24 hours after the first oral dose of flunarizine (4 × 20 mg) or placebo. The results again indicated that in patients flunarizine significantly reduced the echinocyte formation in stored blood samples.

Based on the results of earlier studies it is postulated that flunarizine exerts its effect at the plasma membrane of the erythrocyte by inhibiting excessive influx of extracellular Ca²⁺. This mechanism of action, by which the compound suppresses echinocyte formation, may be similar to that by which it reduces hyperviscosity and possibly improves red blood cell (RBC) deformability.

Get full access to this article

View all access options for this article.

References

Dormandy, J.A. , Hoare, E. , Colley , J. , et al.: Clinical haemodynamic, rheological and biochemical findings in 126 patients with intermittent claudication . Br. Med. J., 4: 581-583, 1973.

De Cree, J. , De Cock, W. , Geukens, H. , et al.: The rheological effects of cinnarizine and flunarizine in normal and pathological conditions. Clinical Research Report, Marbella, October 28-November 2, 1978.

Reid, H.L. , Dormandy, J.A. , Barnes, A.J. , et al.: Impaired red cell deformability in peripheral vascular disease . Lancet, 4: 666-668, 1976.

Verhaegen, H. , Roels, V. , Adriaensen , H. , et al.: The arteriolar effects of cinnarizine and flunarizine. Multitechnical investigations in normal volunteers and in patients with occlusive disease of the extremities secondary to arteriosclerosis . Angiology, 25: 261-278, 1974.

Staessen, A.J. : Treatment of circulatory disturbances with flunarizine and cinnarizine. A multicentre, double-blind and placebo-controlled evaluation. Vasa, 6: 59-71, 1977.

De Cree, J. , Geukens, H. , Verhaegen, H. : Einfluss von Flunarizine (SibeliumR) auf das arterielle Blutstromverhalten . Munch. Med. Wochenschr., 120: 627-630, 1978.

Domschky, K. , Nelson, M. , Dammhayn , B. , et al.: Flunarizin bei Patienten mit zerebraler und peripherer Mangeldurchblutung. Multizentrische doppelblind Studie. Med. Welt., 28: 1062-1064, 1977.

Jageneau, A. , Loots, W. , Brugmans , J. : Prolongation of anoxia-induced hyperemia in healthy middle-aged men treated with cinnarizine and flunarizine . Arzneim. Forsch. (Drug Res.), 24: 1839-1841, 1974 .

Brugmans, J. , Jageneau, A. , Adriaensen , H. : Behandlung von peripheren Durchblutungstörungen der unteren Extremitäten mit Flunarizin und Papaverin . Med. Welt., 28: 1056-1062, 1977 .

10.

De Clerck, F. , De Cree, J. , Brugmans , J. , et al.: Reduction by flunarizine of the increase of blood viscosity after ischaemic forearm occlusion. Arch. Int. Pharmacodyn. Ther., 230: 321-323, 1977.

11.

Scott, C. , Perciso, F.J. , Carpenter, K. , et al.: The effect of flunarizine on human red blood cells. Angiology (in press).

12.

Weed, R.I. , La Celle, P.L. : Metabolic dependence of red cell deformability. J. Clin. Invest. , 48: 795-809, 1969.

13.

Weed, R.I. , Chailly, B. : Calcium-pH interactions in the production of shape change in erythrocytes , in Red Cell Shape. Physiology, Pathology, Ultrastructure . Edited by M. Bessis , R. I. Weed , P. F. Leblond. New York, Heidelberg, Berlin, Springer Verlag, 1973, pp. 55-67.

14.

Palek, J. , Liu, A. , Liu, D. , et al.: Effect of procain HCl on ATP: Calcium dependent alterations in red cell shape and deformability. Blood, 50: 155-164, 1977.

15.

Anderson, D.R. , Davis, J.L. , Caraway , K.L. : Calcium-promoted changes of the human erythrocyte membrane. Involvement of spectrin, transglutaminase, and a membrane-bound protease. 252: 6617-6623, 1977 .

16.

Rogausch, H. : Influence of Ca2+ on red cell deformability and adaptation to sphering agents. Pflugers Arch., 373: 43-47, 1978.

17.

Brecher, G. , Bessis, M. : Present status of spiculed red cells and their relationship to the discocyte-echinocyte transformation: A critical review. Blood, 40: 333-344, 1972.

18.

Bessis, M. : Red cell shapes. An illustrated classification and its rationale, in Red Cell Shape. Physiology, Pathology, Ultrastructure. Edited by M. Bessis , R. I. Weed , P. F. Leblond. New York, Heidelberg, Berlin , Springer Verlag 1973, pp. 1-25.

19.

Nakao, M. , Nakao, T. , Yamazoe, S. : Adenosine triphosphate and maintenance of shape of the human red cells . Nature, 187: 945-946, 1960.

20.

Hochmuth, R.M. , Mohandas, N. : Metabolic dependence of red cell shape: observations with the scanning electron microscope. Microvasc. Res., 4: 295-297, 1972.

21.

Féo, C.J. , Leblond, P.F. : The discocyte-echinocyte transformation comparison of normal and ATP-enriched human erythrocytes. Blood, 44: 639-647, 1974.

22.

Palek, J. , Liu, S.C. , Snijder, L.M. : Metabolic dependence of protein arrangement in human erythrocyte membranes. I. Analysis of spectrin-rich complexes in ATP-depleted red cells. Blood, 51: 385-395, 1978.

23.

Allan, D. , Michell, R.H. : Accumulation of 1,2-diacylglycerol in the plasma membrane may lead to echinocyte transformation of erythrocytes. Nature, 258: 348-349, 1975.

24.

Van Nueten, J.M. , Van Beek, J. , Janssen , P.A.J. : Effect of flunarizine on calcium-induced responses of peripheral vascular smooth muscle. Arch. Intern. Pharmacodyn. Ther., 232: 42-52, 1978.

25.

Van Nueten, J.M. , Van Beek, J. , Janssen P.A.J. : The vascular effects of flunarizine as compared with those of other clinically used vasoactive substances. Submitted for publication.